You are here:

Latest News
 

  • Neuralstem Introduces Novel Therapies for ALS at BIO CEO & Investor Conference

    Neuralstem Introduces Novel Therapies for ALS at BIO CEO & Investor Conference

    Dual platform regenerative medicine company, Neuralstem, Inc., is wrapping up its participation in the 17th Annual BIO CEO & Investor Conference taking place February 9 to the 10th at the Waldorf Astoria in New York. President and CEO, Richard Garr, was invited to present on the company’s proprietary therapeutic technology indicated for the treatment of diseases that affect the central nervous system, […]

  • ALS Tissue-Engineered Skin May Hold Key to Early Diagnoses

    ALS Tissue-Engineered Skin May Hold Key to Early Diagnoses

    A recent study, titled, “Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients,” published in the journal, Acta Neuropathologica Communications, details the creation of a novel tissue-engineered skin model for amyotrophic lateral sclerosis (ALS). ALS is a progressive neurodegenerative disease that specifically affects the motor nerve cells in the brain and […]

  • ALS Ice Bucket Challenge Funds its First Research Project in Canada

    ALS Ice Bucket Challenge Funds its First Research Project in Canada

    The ALS Society of Canada is proud to announce the first research project on amyotrophic lateral sclerosis (ALS) to receive funding raised from the viral ALS Ice Bucket Challenge. The Society also thanks the generous support of national non-profit organization, Brain Canada, and the Canadian Government. The Arthur J. Hudson Translational Team Grant will be used to study the clinical response of ALS patients to a […]

  • ALS Study Reveals a Domain Crucial for Degradation of Misfolded Proteins

    ALS Study Reveals a Domain Crucial for Degradation of Misfolded Proteins

    A recent study published in the journal Molecular Cell, revealed that a specific domain in a particular heat-shock protein plays a major role in the degradation of misfolded proteins. The study is entitled “The Hsp104 N-Terminal Domain Enables Disaggregase Plasticity and Potentiation”. Disorders such as Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) are […]

  • ALS Gene Variant May Be Accelerating Disease in One-Third of Patients

    ALS Gene Variant May Be Accelerating Disease in One-Third of Patients

    A team of researchers from the Penn State College of Medicine found that a specific gene variant found in a third of patients with Amyotrophic lateral sclerosis (ALS) is associated with faster disease progression. The results were found in mice models of ALS carrying only this gene variant, compared to mice that had the standard […]

  • Regulation of Enzyme HDAC6 May Be Relevant in ALS Treatment

    Regulation of Enzyme HDAC6 May Be Relevant in ALS Treatment

    A new study entitled “HDAC6 Is a Bruchpilot Deacetylase that Facilitates Neurotransmitter Release” was published in Cell Reports by Katarzyna Miskiewicz and Liya E. Jose, co-first authors of the study and part of Dr. Patrik Verstreken’s group from the VIB Center for the Biology of Disease and Center for Human Genetics and Leuven Research Institute […]

  • Inhibition of Neural Pumps May Hold Key to ALS Treatment Efficacy

    Inhibition of Neural Pumps May Hold Key to ALS Treatment Efficacy

    Last November, Dr. Piera Pasinelli, Ph.D., associate professor of neuroscience and Co-Director of the Weinberg Unit for ALS Research at Thomas Jefferson University, and her research team made an important discovery in the field of amyotrophic lateral sclerosis (ALS) research that may change the way the therapeutic protocols currently used to treat this debilitating disease […]

  • New Enzyme May Help Treat ALS By Modulating Inflammation

    New Enzyme May Help Treat ALS By Modulating Inflammation

    Researchers at The Scripps Research Institute in California found that a particular enzyme has a harmful ability to create inflammatory lipid molecules in the brain, and is implicated in a rare neuroimmunological disorder, called PHARC – characterized by polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract. The disorder usually begins onset during adolescence and gradually gets worse with age. Amyotrophic Lateral Sclerosis (ALS) is a condition that affects […]

  • Newron Pharma Enrolling Patients for Phase 2 Study on ALS Therapy

    Newron Pharma Enrolling Patients for Phase 2 Study on ALS Therapy

    Newron Pharmaceuticals is about to initiate its Phase II clinical trial, designed to evaluate novel molecule sNN0029 in patients who suffer from Amyotrophic Lateral Sclerosis (ALS), according to information provided by the company in a press release. The company, which has been dedicated to providing CNS and pain therapies, will conduct the Phase II study to assess sNN0029’s safety and […]

  • 7 Celebrities Who Can’t Live Without Their Sheet Masks!

    7 Celebrities Who Can’t Live Without Their Sheet Masks!

    Sheet masks are all the rage these days and celebrities can’t get enough of them! There are many reasons to love sheet masks (portable, hygienic, etc), and as funny as they may look, they pack a serious punch when it comes to skin care. Check out these seven celebs who love them: 1. Diane Kruger This is the […]